Generic name:ansuvimab-zykl (intravenous route) [ an-SOO-vi-mab-- zykl ]
Medically reviewed by Drugs.com. Last updated on May 30, 2022.
Commonly used brand name(s)
In the U.S.
- Ebanga
Pharmacologic Class: Ansuvimab
Uses for Ebanga
Ansuvimab-zykl injection is used to treat infection caused by Zaire ebolavirus.
This medicine is to be given only by or under the direct supervision of your doctor.
Before using Ebanga
In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered:
Allergies
Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.
Pediatric
Appropriate studies performed to date have not demonstrated pediatric-specific problems that would limit the usefulness of ansuvimab-zykl injection in the pediatric population. Safety and efficacy have been established.
Geriatric
Although appropriate studies on the relationship of age to the effects of ansuvimab-zykl injection have not been performed in the geriatric population, no geriatric-specific problems have been documented to date.
Breastfeeding
There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.
Interactions with medicines
Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. When you are receiving this medicine, it is especially important that your healthcare professional know if...
